Landscapes / Companies
Nanjing IASO Biotechnology Co., Ltd. not checked
FollowEvery new trial, moved date and filing, and a Monday email
Drugs
5
in active trials
Trials
9 active
11 since 2021
Drugs5
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Gene therapy substances |
Approved in China | Jun 2027Phase 2 trial completes | |||
| How it works | A gene therapy | ||||
| Next date | Jun 2027 · Phase 2 trial completes | ||||
| Also tested for | Multiple Myeloma, AL Amyloidosis and 2 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | — | |||
| Also tested for | B-cell Non-Hodgkin's Lymphoma | ||||
| Open drug page | |||||
— |
Phase 1 | 8 May 2028Phase 1 trial completes | |||
| Next date | 8 May 2028 · Phase 1 trial completes | ||||
| Also tested for | Systemic Lupus Erythematosus, Lupus Nephritis | ||||
| Open drug page | |||||
— |
Phase 1 | 21 May 2028Phase 1 trial completes | |||
| Next date | 21 May 2028 · Phase 1 trial completes | ||||
| Also tested for | Large B-cell Lymphoma | ||||
| Open drug page | |||||
— |
Phase 1 | — | |||
| Also tested for | Relapsed/Refractory Multiple Myeloma, Plasma Cell Leukemia | ||||
| Open drug page | |||||
About
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 Industry-sponsored drug trials since 2021